|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
普维替尼在HER2表达阳性晚期实体瘤患者中的耐受性及药代动力学研究
[Translation] Study on the tolerability and pharmacokinetics of pvitinib in patients with HER2-positive advanced solid tumors
评价HER2表达阳性晚期实体瘤患者单次及后续多次口服普维替尼胶囊的安全性、耐受性和药代动力学特征,为后期临床试验的方案设计提供依据
[Translation] To evaluate the safety, tolerability and pharmacokinetic characteristics of single and subsequent oral administration of Provitinib Capsules in patients with HER2-positive advanced solid tumors, and to provide a basis for the design of later clinical trials
100 Clinical Results associated with Hangzhou Derun Yucheng Biotechnology Co., Ltd.
0 Patents (Medical) associated with Hangzhou Derun Yucheng Biotechnology Co., Ltd.
100 Deals associated with Hangzhou Derun Yucheng Biotechnology Co., Ltd.
100 Translational Medicine associated with Hangzhou Derun Yucheng Biotechnology Co., Ltd.